- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05230537
Zamaskowane, kontrolowane placebo badanie oceniające iptacopan w zwyrodnieniu plamki żółtej związanym z wiekiem
Randomizowane, z maską uczestników i badaczy, kontrolowane placebo, wieloośrodkowe badanie potwierdzające słuszność koncepcji w celu oceny bezpieczeństwa i skuteczności LNP023 (iptacopan) u pacjentów z wczesnym i pośrednim zwyrodnieniem plamki żółtej związanym z wiekiem
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).
Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:
- Iptacopan (LNP023) oral capsules
- Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Shanghai, Chiny, 200080
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chiny, 150001
- Novartis Investigative Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chiny, 300020
- Novartis Investigative Site
-
-
-
-
-
Arecibo, Portoryko, 00612
- Emanuelli Research and Development Center LLC
-
-
-
-
California
-
Fullerton, California, Stany Zjednoczone, 92835
- Retina Consultants of Orange County
-
Huntington Beach, California, Stany Zjednoczone, 92647
- Salehi Retina Institute
-
Rancho Cordova, California, Stany Zjednoczone, 95670
- Martel Eye Medical Group
-
Sacramento, California, Stany Zjednoczone, 95841
- Retinal Consultants Medical Group Inc
-
Santa Barbara, California, Stany Zjednoczone, 93103
- California Retina Consultants
-
-
Colorado
-
Durango, Colorado, Stany Zjednoczone, 81303
- Southwest Retina Research Center
-
-
Florida
-
Deerfield Beach, Florida, Stany Zjednoczone, 33064
- Advanced Research LLC
-
Delray Beach, Florida, Stany Zjednoczone, 33484
- Retina Center Of South Florida
-
St. Petersburg, Florida, Stany Zjednoczone, 33711
- Retina Vitreous Associates of Florida
-
-
Indiana
-
Carmel, Indiana, Stany Zjednoczone, 46032
- Midwest Eye Institute
-
-
Louisiana
-
Metairie, Louisiana, Stany Zjednoczone, 70001
- Retina Associates New Orleans
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21209
- Retina Care Center
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Opthamalic Consultants of Boston
-
-
New Jersey
-
Bloomfield, New Jersey, Stany Zjednoczone, 07003
- Envision Ocular LLC
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27705
- Duke Eye Center
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97210
- Retina Northwest PC
-
-
Tennessee
-
Germantown, Tennessee, Stany Zjednoczone, 38138
- Charles Retina Institute
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78793
- Austin Research Center for Retina
-
Bellaire, Texas, Stany Zjednoczone, 77401
- Retina Consultants TX Rsrch Ctr
-
Dallas, Texas, Stany Zjednoczone, 75231
- Retina Foundation
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Texas Retina Associates
-
Houston, Texas, Stany Zjednoczone, 77030
- Retina Consultants of Houston PA
-
-
-
-
-
London, Zjednoczone Królestwo, SE5 9RS
- Novartis Investigative Site
-
Southampton, Zjednoczone Królestwo, SO16 6YD
- Novartis Investigative Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male or female participants ≥ 50 years of age
- Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
- Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
- Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
- Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
- If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.
Exclusion Criteria:
- History or current diagnosis of ECG abnormalities indicating significant safety risk, such as clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
- History of familial long QT syndrome or known family history of Torsades de Pointes
- History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
- History of end stage kidney disease requiring dialysis or renal transplant
- History of malignancy of any organ system
- History of solid organ or bone marrow transplantation
- History of recurrent meningitis or history of meningococcal infections despite vaccination
- History of immunodeficiency diseases, including a positive Human Immunodeficiency Virus test result at Screening
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
- Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
- Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Iptacopan (LNP023)
Iptacopan (LNP023) oral use capsules |
oral capsules |
|
Komparator placebo: Placebo
Placebo matched to study drug, oral use capsules |
oral capsules |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging
Ramy czasowe: Baseline/Day 1 through Month 24
|
OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines |
Baseline/Day 1 through Month 24
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
The incidence of ocular and non-ocular adverse events (AEs)
Ramy czasowe: Baseline/Day 1 through Month 24
|
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. |
Baseline/Day 1 through Month 24
|
|
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye
Ramy czasowe: Baseline/Day 1 through Month 24
|
Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye
Ramy czasowe: Baseline/Day 1 through Month 24
|
ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye
Ramy czasowe: Baseline/Day 1 through Month 24
|
Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read. |
Baseline/Day 1 through Month 24
|
|
Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye
Ramy czasowe: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
|
Pharmacokinetics - concentrations of LNP023 related to trough samples
Ramy czasowe: Baseline/Day 1 through Month 24
|
Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method. |
Baseline/Day 1 through Month 24
|
|
Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye
Ramy czasowe: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CLNP023E12201
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .